U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® for Adults With Moderately to Severely Active Crohn's Disease
AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on Phase 3 AFFIRM trial results showing superior clinical remission and endoscopic response at week 12 compared to placebo, particularly in patients without prior advanced therapy failure.
How this was made
The 30-second read
Why it matters
The new SC option could improve patient adherence and expand market share in Crohn's disease therapy.
Market read
Regulatory approval is a primary catalyst for AbbVie, likely prompting short-term price appreciation.
What to watch
Reimbursement negotiations and competition from other IL-23 inhibitors could temper growth.
Background
AbbVie announced FDA approval for a subcutaneous induction regimen of SKYRIZI, previously available only intravenously.
Ticker impact
FDA approval of subcutaneous SKYRIZI induction regimen for Crohn's disease expands AbbVie's product offering and may boost sales.
upward pressure as investors price in additional sales opportunity
Regulatory approval is a material catalyst; the SC formulation addresses patient convenience and could capture market share from competitors.
Market effects
May strengthen the biotech/IBD therapeutic segment and pressure rivals with IV-only formulations.
U.S. market focus, but could influence global Crohn's disease treatment landscape.
Limited to healthcare sector; broader market impact modest.
Counterpoint
If adoption is slower than expected, the approval may not translate into near-term revenue, limiting upside.
Key entities
- CompanyAbbVie
Pharmaceutical company receiving FDA approval for SKYRIZI SC induction.
- Regulatory AgencyFDA
U.S. Food and Drug Administration granting the approval.
